Zirconium-89 (89Zr) Radiopharmaceutics Developed for ImmunoPET
Articles > Review · 2021
Authors: Burcu Altıparmak Güleç, Fatma YURT
Manisa Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, National Refreed University Journal, National, 2021, vol 8, pp 534-542
Summary
<p>A wide variety and comprehensive research are being conducted on the development of molecular imaging agents used in imaging cancer tissue. Positron Emission Tomography (PET) radiopharmaceuticals consist of a positronemitting radionuclide and a molecular structure. 89Zr-labeled monoclonal antibodies (mAb), peptides, nanoparticles, proteins, and other compounds, called 89Zr-Immuno-PET, have been used in cancerous tissue imaging. In this review, the potential of 89Zr radionuclide-labeled pharmaceuticals, which are widely used in Immuno-PET imaging with their long half-life, in pre-clinical and clinical studies conducted in the last five years were reviewed and discussed. <br></p>